New study demonstrates tissue regenerative potential of chemoattractant delivery system

NewsGuard 100/100 Score

A new study has demonstrated the tissue regenerative potential of a chemoattractant delivery system that can draw mesenchymal stem cells (MSCs) to the site of intervertebral disc (IVD) degeneration. The study, carried out in a cow model of IVD degeneration, not only showed the recruitment of regenerative cells, but also reported increased collagen production, as described in an article published in Tissue Engineering, Part A, peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Raquel Madeira Gonçalves, PhD, Universidade do Porto, Portugal and a team of researchers from Universidade do Porto and the AO Research Institute Davos, Switzerland, described the hyaluronan based-chemoattractant delivery system they developed in the article entitled "Stromal Cell Derived Factor-1-Mediated Migration of Mesenchymal Stem Cells Enhances Collagen Type II Expression in Intervertebral Disc." In the presence of the system, which contained stromal cell derived factor-1 (SDF-1), migration of MSCs to the degenerative site was enhanced. In addition, the researchers measured higher levels of collagen type II and of pro-catabolic factors produced by the MSCs that would contribute to enhanced remodeling of the extracellular matrix.

"This study exemplifies the impact of drug delivery on enhancing a specific cellular activity and thus reverting a tissue degenerative process," says Tissue Engineering Co-Editor-in-Chief Antonios G. Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Yokogawa helps to revolutionize the field of single-cell lipidomics